

RetinalGenix Technology

Herbert L Gould* and Jerry Katzman

Associate Clinical Professor (Emeritus), NY Medical College, United States

***Corresponding Author:** Herbert L Gould, Associate Clinical Professor (Emeritus), NY Medical College, United States.

Received: February 28, 2023; **Published:** March 17, 2023

RetinalGenix Technologies allows healthcare providers to use retinal imaging and genetic mapping to monitor and screen patients from their homes to provide diagnoses of systemic diseases including heart disease, Alzheimer's, dementia, Parkinson's and more.

"We believe this platform to be a breakthrough in advanced retinal imaging and genetic mapping that could become a new standard for the diagnosis of systemic disease and could replace expensive and time-consuming procedures such as CT, MRI and PET at a much lower cost. The RetinalGeniX DNA/GPS platform offers an opportunity to bring testing away from laboratories and hospitals and into primary care centers, where it could be handled by practitioners at a cost that is a fraction of that of a CT scan, an MRI or an echo machine.

The new platform is being designed to enable us to determine the right patients to screen and should assist healthcare providers to choose the most effective early interventions. This is possible because manifestations of disease are most often seen in the eye. It is widely acknowledged that the eyes are a window to systemic health. It is possible to observe correlations between damage in the retina and kidney disease, high blood pressure and heart problems.

The emergence of high-resolution imaging in modalities and the progress of artificial intelligence, in particular, deep learning, have opened up new pathways to potentially identify science and protectors of systemic disease through the retina.

Mass screening is accomplished by using an affordable high definition 1 mm micro-camera able to image a 200 degree view of the peripheral retina, without dilating the pupil, where the earliest signs of diabetes, hypertension, cardiopathology, dementia and other vascular based diseases are developing. Mass screening could be accomplished in health centers, nursing homes, hospital clinics etc.

With the guidance of RetinalGeniX DNA/GPS, the company intends to focus on patients that have genetic predisposition to multiple systemic diseases. Early diagnosis leads to early treatment and favorable prognosis.

Volume 14 Issue 4 April 2023

©All rights reserved by Herbert L Gould and Jerry Katzman.